Sunday, May 30, 2021

People Want an Alzheimer’s Drug. Aducanumab Isn’t the One.

An F.D.A. sign-off for aducanumab would make finding a good treatment harder.

from NYT > Top Stories https://ift.tt/34psXgz
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

A Wildlife Regulator’s Family Business Had a Permit to Renew. She Stepped In.

Jenifer Chatfield, a top official at the Interior Department, faces scrutiny from ethics experts for actions that could help her family’s bu...